BsAb (anti-IL-1β and anti-IL-17A) had beneficial effects on clinical symptom and histological lesion of CIA mice.
BsAb had therapeutic effect, superior to Adalimumab and Dexamethasone in the aspect of inflammation cytokines.
BsAb could suppress NF-κB pathway and ameliorate the vicious circle of IL-1β and IL-17A.